Clinical/Translational Research

The Division has a number of faculty members involved in various clinical and translational research activities. View a list of faculty and their research interests by category below.

Antibiotic stewardship

  • Anne Mobley Butler, PhD, MS – Applying epidemiologic methods to clinical and claims data to study the prevention and treatment of common infections
  • Michael Durkin, MD – Improving patient care by reducing healthcare-associated infections.
  • Kevin Hsueh, MD – Improving patient safety, and the efficiency and efficacy of healthcare delivery.
  • Michael Lane, MD, MPHS, MSc – Improving the safety, quality and effectiveness of care.
  • Caline Mattar, MD – Antimicrobial resistance and infection prevention in resource limited settings

Bioinformatics, healthcare quality, patient safety and administrative data

  • Thomas C. Bailey, MD – Information technology to improve healthcare quality.
  • Jason P. Burnham, MD – epidemiology of multidrug-resistant organisms and improving outcomes for patients who have them.
  • Anne Mobley Butler, PhD, MS – Applying epidemiologic methods to clinical and claims data to study the prevention and treatment of common infections

 

  • Victoria J. Fraser, MD – Use of large administrative data for risk prediction models, outcomes, costs and epidemiology of hospital acquired infections, antibiotic resistance, surgical site infections and adverse events.
  • William Claiborne Dunagan, MD, MS – Assessment and improvement of health care quality and patient safety.
  • Jennie H. Kwon, DO, MSCI – Multidrug-resistant organism transmission dynamics, Clostridium difficile infections, healthcare epidemiology, patient safety and quality improvement.
  • Michael Lane, MD, MPHS, MSc – Improving clinical outcomes and the quality of care.
  • Margaret A. Olsen, PhD, MPH – Epidemiology of hospital acquired infections, particularly surgical site infections, and use of claims data for health outcomes research.
  • Mohammed (Rayan) J. Saeed, MBChB, MPH – Using large data to conduct observational research, to improve risk adjustment models for surgical site infections (SSI) to allow better comparison of infection risk between hospitals.
  • Keith F. Woeltje, MD, PhD – Improving the quality of healthcare delivery, especially in the area of preventing healthcare-associated infections (HAI).

C. difficile infection

  • Erik Dubberke, MD – Blood stream infection and Clostridium difficile associated disease in transplant and oncology patients.
  • Jennie H. Kwon, DO, MSCI – Multidrug-resistant organism transmission dynamics, Clostridium difficile infections, healthcare epidemiology, patient safety and quality improvement.

Diagnostics and clinical microbiology

  • Neil W. Anderson, MD – Identifying microorganisms from blood cultures.
  • Carey-Ann Burnham, PhD – Antimicrobial resistance, with a focus on the transmission and epidemiology of multidrug resistant organisms (MDROs).
  •  Gregory Storch, MD – Virology and the molecular identification of new and emerging pathogens.

Global health

  • Philip Budge, MD, PhD – The global elimination and control of lymphatic fliariasis (LF) and other neglected tropical diseases.
  • Rupa Patel, MD, MPH, DTM&H – HIV prevention strategies among high-risk groups.
  • Caline Mattar, MD – Antimicrobial Resistance, infection prevention and interventions to promote appropriate antibiotic use in resource limited settings, international health and travel medicine.
  • William G. Powderly, MD – HIV/AIDS, complications of antiretroviral therapy.
  • Andrej Spec, MD, MSCI – fungal infections, particularly in immunocompromised patients, including those with transplants; research focuses on Cryptococcus, Histoplasma, Candida, Aspergillus and other invasive molds. He studies the epidemiology and factors that affect outcomes in patients infected with fungus, both in the United States and globally in resource limited settings of Guatemala and Ethiopia. He serves as the Associate Director of our Infectious Disease Clinical Research Unit (ID-CRU) and is actively involved in the Mycoses Study Group (MSG), through which he participates and runs multicenter studies focused on new diagnostic tests and treatments for invasive fungal infections; creator and leader of the Washington University Mycoses Group (a consortium of researchers interested in fungal infections).
  • Gary J. Weil, MD – Clinical parasitology, tropical medicine, travel medicine and international health.

Hospital epidemiology/infection prevention

  • Hilary M. Babcock, MD, MPH – Occupational exposures and nosocomial infections.
  • Anne Mobley Butler, PhD, MS – Applying epidemiologic methods to clinical and claims data to study the prevention and treatment of common infections
  • Courtney Chrisler, MD – Adverse events requiring hospital readmission.
  • Erik Dubberke, MD – Blood stream infection and Clostridium difficile associated disease in transplant and oncology patients.
  • Michael Durkin, MD – Improving patient care by reducing healthcare-associated infections.
  • Victoria J. Fraser, MD – Multicenter and single center studies of the epidemiology, risk factors, surveillance, outcomes and interventions to prevent hospital acquired infections and antimicrobial resistance.
  • Jennie H. Kwon, DO, MSCI – Multidrug-resistant organism transmission dynamics, Clostridium difficile infections, healthcare epidemiology, patient safety and quality improvement.
  • Stephen Y. Liang, MD, MPHS – Trauma-related infections, orthopedic infections, skin and soft tissue infections, device infections, infection prevention.
  • Jay R. McDonald, MD – Infection control, antimicrobial resistance, surgical site infections.
  • Margaret A. Olsen, PhD, MPH – Epidemiology of hospital acquired infections, particularly surgical site infections, and use of claims data for health outcomes research.
  • Mohammed (Rayan) J. Saeed, MBChB, MPH – Using large data to conduct observational research, to improve risk adjustment models for surgical site infections (SSI) to allow better comparison of infection risk between hospitals.
  • David K. Warren, MD, MPH – Epidemiology and prevention of healthcare-associated infections.
  • Keith F. Woeltje, MD, PhD – Improving the quality of healthcare delivery, especially in the area of preventing healthcare-associated infections (HAI).

HIV

Immunocompromised/host transplant infectious diseases

  • Erik Dubberke, MD – Blood stream infection and Clostridium difficile associated disease in transplant and oncology patients.
  • Andrej Spec, MD, MSCI – fungal infections, particularly in immunocompromised patients, including those with transplants; research focuses on Cryptococcus, Histoplasma, Candida, Aspergillus and other invasive molds; serves as the Associate Director of our Infectious Disease Clinical Research Unit (ID-CRU) and is actively involved in the Mycoses Study Group (MSG), through which he participates and runs multicenter studies focused on new diagnostic tests and treatments for invasive fungal infections; creator and leader of the Washington University Mycoses Group (a consortium of researchers interested in fungal infections).

Invasive Fungal Infections

  • William G. Powderly, MD – HIV/AIDS, opportunistic infections; cryptococcus, complications of antiretroviral therapy.
  • Andrej Spec, MD, MSCI – fungal infections, particularly in immunocompromised patients, including those with transplants; research focuses on Cryptococcus, Histoplasma, Candida, Aspergillus and other invasive molds; serves as the Associate Director of our Infectious Disease Clinical Research Unit (ID-CRU) and is actively involved in the Mycoses Study Group (MSG), through which he participates and runs multicenter studies focused on new diagnostic tests and treatments for invasive fungal infections; creator and leader of the Washington University Mycoses Group (a consortium of researchers interested in fungal infections).

Outpatient Parenteral Antimicrobial Therapy

  • Yasir Hamad, MD – Outpatien Antimicrobial Therapy, Co-chair of OPAT
  • Caline Mattar, MD – Outpatient Antimicrobial Therapy Committee
  • Yvonne Burnett, PharmD – Clinical Pharmacy Specialist, Infectious Disease OPAT Team; Co-chair of OPAT

 

Sexually Transmitted Diseases (STDs)